Cerevel Net Tangible Assets vs Current Deferred Revenue Analysis

CERE Stock

USD 41.00 0.33 0.80%

Cerevel Therapeutics financial indicator trend analysis is way more than just evaluating Cerevel Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cerevel Therapeutics is a good investment. Please check the relationship between Cerevel Therapeutics Net Tangible Assets and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cerevel Therapeutics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Net Tangible Assets vs Current Deferred Revenue

Net Tangible Assets vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cerevel Therapeutics Net Tangible Assets account and Current Deferred Revenue. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Cerevel Therapeutics' Net Tangible Assets and Current Deferred Revenue is 0.91. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Cerevel Therapeutics Holdings, assuming nothing else is changed. The correlation between historical values of Cerevel Therapeutics' Net Tangible Assets and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Cerevel Therapeutics Holdings are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Net Tangible Assets i.e., Cerevel Therapeutics' Net Tangible Assets and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.91

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Cerevel Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cerevel Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cerevel Therapeutics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

At present, Cerevel Therapeutics' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 523.9 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (15.12).

	2021	2022	2023	2024 (projected)
Total Operating Expenses	220.1M	367.8M	441.6M	463.7M
Cost Of Revenue	2.7M	4.9M	5.6M	4.2M

Total Operating Expenses Cost Of Revenue

Cerevel Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Total Assets		0.97	0.97	0.92	0.8	0.52	0.77	-0.62	-0.92	0.52	0.89	0.87	0.38	1.0	0.91	-0.31	0.42	0.83	0.96	-0.74	0.72	0.89	0.96	0.59	1.0	0.37
Short Long Term Debt Total	0.97		1.0	0.96	0.84	0.51	0.81	-0.55	-0.96	0.6	0.86	0.92	0.4	0.96	0.95	-0.28	0.4	0.9	1.0	-0.77	0.76	0.93	1.0	0.58	0.96	0.42
Other Current Liab	0.97	1.0		0.94	0.81	0.45	0.77	-0.53	-0.95	0.61	0.85	0.9	0.34	0.96	0.95	-0.24	0.41	0.9	0.99	-0.73	0.75	0.91	0.99	0.53	0.96	0.39
Total Current Liabilities	0.92	0.96	0.94		0.95	0.64	0.9	-0.52	-0.99	0.75	0.82	0.95	0.43	0.91	0.9	-0.31	0.38	0.94	0.96	-0.75	0.9	0.98	0.97	0.69	0.91	0.39
Total Stockholder Equity	0.8	0.84	0.81	0.95		0.77	0.95	-0.48	-0.94	0.78	0.72	0.93	0.49	0.79	0.78	-0.4	0.31	0.88	0.85	-0.72	0.96	0.97	0.87	0.81	0.79	0.38
Property Plant And Equipment Net	0.52	0.51	0.45	0.64	0.77		0.85	-0.23	-0.59	0.48	0.39	0.66	0.75	0.51	0.37	-0.58	0.37	0.6	0.54	-0.74	0.76	0.7	0.56	0.99	0.51	0.51
Current Deferred Revenue	0.77	0.81	0.77	0.9	0.95	0.85		-0.45	-0.86	0.64	0.69	0.9	0.72	0.76	0.72	-0.31	0.33	0.83	0.82	-0.87	0.9	0.92	0.84	0.87	0.76	0.55
Net Debt	-0.62	-0.55	-0.53	-0.52	-0.48	-0.23	-0.45		0.55	-0.13	-0.89	-0.63	-0.23	-0.59	-0.73	0.19	0.43	-0.21	-0.48	0.33	-0.24	-0.55	-0.49	-0.32	-0.59	-0.18
Retained Earnings	-0.92	-0.96	-0.95	-0.99	-0.94	-0.59	-0.86	0.55		-0.76	-0.83	-0.96	-0.36	-0.91	-0.92	0.32	-0.34	-0.92	-0.96	0.7	-0.87	-0.98	-0.97	-0.66	-0.91	-0.33
Accounts Payable	0.52	0.6	0.61	0.75	0.78	0.48	0.64	-0.13	-0.76		0.38	0.63	0.05	0.53	0.53	-0.1	0.38	0.8	0.63	-0.36	0.85	0.73	0.64	0.54	0.52	0.09
Cash	0.89	0.86	0.85	0.82	0.72	0.39	0.69	-0.89	-0.83	0.38		0.86	0.34	0.87	0.94	-0.26	-0.04	0.6	0.82	-0.6	0.54	0.82	0.83	0.48	0.87	0.33
Non Current Assets Total	0.87	0.92	0.9	0.95	0.93	0.66	0.9	-0.63	-0.96	0.63	0.86		0.5	0.85	0.92	-0.4	0.18	0.84	0.91	-0.74	0.81	0.98	0.92	0.72	0.85	0.37
Non Currrent Assets Other	0.38	0.4	0.34	0.43	0.49	0.75	0.72	-0.23	-0.36	0.05	0.34	0.5		0.37	0.3	-0.21	0.19	0.36	0.41	-0.87	0.43	0.45	0.43	0.73	0.38	0.83
Cash And Short Term Investments	1.0	0.96	0.96	0.91	0.79	0.51	0.76	-0.59	-0.91	0.53	0.87	0.85	0.37		0.89	-0.29	0.46	0.84	0.96	-0.74	0.72	0.88	0.96	0.57	1.0	0.37
Net Receivables	0.91	0.95	0.95	0.9	0.78	0.37	0.72	-0.73	-0.92	0.53	0.94	0.92	0.3	0.89		-0.25	0.1	0.77	0.92	-0.63	0.64	0.89	0.92	0.46	0.89	0.33
Common Stock Total Equity	-0.31	-0.28	-0.24	-0.31	-0.4	-0.58	-0.31	0.19	0.32	-0.1	-0.26	-0.4	-0.21	-0.29	-0.25		-0.13	-0.28	-0.29	0.2	-0.31	-0.41	-0.3	-0.57	-0.3	-0.05
Common Stock Shares Outstanding	0.42	0.4	0.41	0.38	0.31	0.37	0.33	0.43	-0.34	0.38	-0.04	0.18	0.19	0.46	0.1	-0.13		0.61	0.47	-0.45	0.51	0.32	0.46	0.34	0.46	0.2
Short Term Investments	0.83	0.9	0.9	0.94	0.88	0.6	0.83	-0.21	-0.92	0.8	0.6	0.84	0.36	0.84	0.77	-0.28	0.61		0.93	-0.72	0.92	0.91	0.94	0.64	0.83	0.37
Non Current Liabilities Total	0.96	1.0	0.99	0.96	0.85	0.54	0.82	-0.48	-0.96	0.63	0.82	0.91	0.41	0.96	0.92	-0.29	0.47	0.93		-0.78	0.8	0.93	1.0	0.6	0.96	0.43
Inventory	-0.74	-0.77	-0.73	-0.75	-0.72	-0.74	-0.87	0.33	0.7	-0.36	-0.6	-0.74	-0.87	-0.74	-0.63	0.2	-0.45	-0.72	-0.78		-0.68	-0.73	-0.79	-0.76	-0.74	-0.82
Other Current Assets	0.72	0.76	0.75	0.9	0.96	0.76	0.9	-0.24	-0.87	0.85	0.54	0.81	0.43	0.72	0.64	-0.31	0.51	0.92	0.8	-0.68		0.9	0.81	0.77	0.72	0.34
Other Stockholder Equity	0.89	0.93	0.91	0.98	0.97	0.7	0.92	-0.55	-0.98	0.73	0.82	0.98	0.45	0.88	0.89	-0.41	0.32	0.91	0.93	-0.73	0.9		0.95	0.75	0.88	0.35
Total Liab	0.96	1.0	0.99	0.97	0.87	0.56	0.84	-0.49	-0.97	0.64	0.83	0.92	0.43	0.96	0.92	-0.3	0.46	0.94	1.0	-0.79	0.81	0.95		0.63	0.96	0.43
Property Plant And Equipment Gross	0.59	0.58	0.53	0.69	0.81	0.99	0.87	-0.32	-0.66	0.54	0.48	0.72	0.73	0.57	0.46	-0.57	0.34	0.64	0.6	-0.76	0.77	0.75	0.63		0.58	0.53
Total Current Assets	1.0	0.96	0.96	0.91	0.79	0.51	0.76	-0.59	-0.91	0.52	0.87	0.85	0.38	1.0	0.89	-0.3	0.46	0.83	0.96	-0.74	0.72	0.88	0.96	0.58		0.37
Short Term Debt	0.37	0.42	0.39	0.39	0.38	0.51	0.55	-0.18	-0.33	0.09	0.33	0.37	0.83	0.37	0.33	-0.05	0.2	0.37	0.43	-0.82	0.34	0.35	0.43	0.53	0.37

Click cells to compare fundamentals

Cerevel Therapeutics Account Relationship Matchups

Cerevel Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	14.9M	29.5M	42.5M	72.6M	92.2M	96.8M
Retained Earnings	(244.3M)	(390.9M)	(616.2M)	(967.8M)	(1.4B)	(1.3B)
Accounts Payable	2.1M	5.0M	11.3M	10.1M	11.9M	6.6M
Common Stock Shares Outstanding	127.1M	73.6M	136.6M	151.3B	162.1M	154.0M
Other Current Assets	69K	6.9M	12.3M	13.6M	10.7M	11.2M
Total Current Assets	87.1M	390.6M	(117.8M)	905.7M	1.0B	1.1B
Net Tangible Assets	77.8M	384.5M	578.7M	521.2M	599.4M	326.7M
Other Assets	6.2M	6.1M	0.0	4.8M	4.3M	4.6M
Property Plant Equipment	27.5M	48.6M	51.7M	27.5M	31.6M	34.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

DD	Dupont De Nemours
GM	General Motors
BAC	Bank of America

When determining whether Cerevel Therapeutics is a strong investment it is important to analyze Cerevel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cerevel Therapeutics' future performance. For an informed investment choice regarding Cerevel Stock, refer to the following important reports:

How To Invest In Cerevel

Details

Is Cerevel Stock a good investment?

Details

What is Cerevel Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cerevel Therapeutics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Complementary Tools for Cerevel Stock analysis

When running Cerevel Therapeutics' price analysis, check to measure Cerevel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cerevel Therapeutics is operating at the current time. Most of Cerevel Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cerevel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cerevel Therapeutics' price. Additionally, you may evaluate how the addition of Cerevel Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities

Is Cerevel Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cerevel Therapeutics. If investors know Cerevel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cerevel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.73)

Return On Assets

(0.30)

Return On Equity

(0.92)

The market value of Cerevel Therapeutics is measured differently than its book value, which is the value of Cerevel that is recorded on the company's balance sheet. Investors also form their own opinion of Cerevel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cerevel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cerevel Therapeutics' market value can be influenced by many factors that don't directly affect Cerevel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cerevel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cerevel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cerevel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cerevel Net Tangible Assets vs Current Deferred Revenue Analysis

Net Tangible Assets vs Current Deferred Revenue

Net Tangible Assets vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Net Tangible Assets

Current Deferred Revenue

Cerevel Therapeutics fundamental ratios Correlations

Cerevel Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cerevel Therapeutics fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Cerevel Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Other Current Liab	+ 1.0	Short Long Term Debt Total
Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Short Long Term Debt Total
Total Current Assets	+ 1.0	Cash And Short Term Investments

Retained Earnings	- 0.99	Total Current Liabilities
Other Stockholder Equity	- 0.98	Retained Earnings
Total Liab	- 0.97	Retained Earnings
Non Current Liabilities Total	- 0.96	Retained Earnings
Non Current Assets Total	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Short Long Term Debt Total